| Add to balance / Manage account | User: | Log out |
| Prospect News home > News index > List of issuers E > Headlines for EntreMed Inc. > News item |
EntreMed's 2ME2 cancer, arthritis treatment receives patent
By Elaine Rigoli
Tampa, Fla., March 16 - EntreMed, Inc. said the U.S. Patent Office issued U.S. Patent No. 7,012,070, which covers methods of treating a broad range of indications with the company's lead clinical-stage compound, 2-methoxyestradiol (2ME2), including solid tumors or tumor metastases and immune and inflammatory diseases such as rheumatoid arthritis.
The patent is owned by Children's Hospital Boston and is licensed exclusively worldwide to EntreMed, according to a company news release.
Panzem NCD, an oral formulation of 2ME2, is currently in phase 2 clinical trials for cancer and preclinical development for rheumatoid arthritis.
EntreMed said 2ME2 is an antimitotic cancer drug that can attack tumors on multiple fronts by disrupting microtubules, an intracellular matrix necessary for the rapid division of cancer cells, by inducing programmed cell death and by blocking blood vessels that feed tumors (angiogenesis).
Angiogenesis is also an integral component of the rheumatoid arthritis disease process. EntreMed said results from preclinical studies support the potential for 2ME2 as a disease modifying anti-rheumatic drug. Antiarthritic activities of 2ME2 were observed in both preventive and treatment studies.
When 2ME2 was administered in the preventive setting, the onset of arthritis was delayed significantly. When 2ME2 was administered in the disease treatment setting, there was marked inhibition of tissue and joint damage, the release said.
Rockville, Md.-based EntreMed is a clinical-stage pharmaceutical company developing therapeutic candidates primarily for the treatment of cancer and inflammation.
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.